Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 7, 2012, Pages 1099-1107

  Perkins, Janelle B ^a   Kim, Jongphil ^a   Anasetti, Claudio ^a   Fernandez, Hugo F ^a   Perez, Lia E ^a   Ayala, Ernesto ^a   Kharfan Dabaja, Mohamed A ^a   Tomblyn, Marcie R ^a   Sullivan, Daniel M ^a   Pidala, Joseph A ^a   Field, Teresa L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Busulfan; Dose escalation; Fludarabine; Hematopoietic cell transplant; Pharmacokinetics

Indexed keywords

BUSULFAN; FLUDARABINE; FLUDARABINE PHOSPHATE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DRB1 ANTIGEN; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COHORT ANALYSIS; DERMATITIS; DIARRHEA; DONOR; DRUG TOLERABILITY; DYSPHAGIA; ENGRAFTMENT; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG TOXICITY; MALE; NEPHROTOXICITY; ORAL MUCOSITIS; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BUSULFAN; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 84862791666     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.12.584     Document Type: Article

References (30)

1. Santos G.W., Tutschka P.J., Brookmeyer R., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983, 309:1347-1353.
2. Grochow L.B. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993, 20(suppl 4):18-25.
3. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996, 17:225-230.
4. Ljungman P., Hassan M., Békássy A.N., Ringdén O., öberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997, 20:909-913.
5. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995, 16:31-42.
6. Slattery J.T., Kalhorn T.F., McDonald G.B., et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996, 14:1484-1494.
7. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000, 6:548-554.
8. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002, 8:145-154.
9. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
10. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003, 102:820-826.
11. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
12. deLima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
13. Perkins J., Field T., Kim J., et al. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone Marrow Transplant 2011, 46:1418-1425.
14. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008, 14:220-228.
15. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
16. Pasquini M.C., Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides Available at:. http://www.cibmtr.org.
17. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
18. Lai W.K., Pang C.P., Law L.K., Wong R., Li C.K., Yuen P.M. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem 1998, 44:2506-2510.
19. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993, 118:255-267.
20. Lobashevsky A.L., Senkbeil R.W., Townsend J.E., Mink C.A., Thomas J.M. Quantitative analysis of chimerism using a short tandem repeat method on a fluorescent automated DNA sequencer. Clin Lab Haematol 2006, 28:40-49.
21. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
22. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
23. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
24. Choudhury J.B. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002, 21:1129-1144.
25. Perkins J., Field T., Kim J., et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16:937-947.
26. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007, 13:56-64.
27. O'Donnell P.H., Artz A.S., Undevia S.D., et al. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma 2010, 51:2240-2249.
28. McDonald G.B. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010, 51:1450-1460.
29. Wood W.A., Waldo C.M., Rao K.V., et al. Identification of an AUC of 7603 umol*min/hr per day 4 days as the maximum tolerated dose of iv continuous infusion busulfan with fixed dose fludarabine in a pharmacokinetically-based dose phase I study in patients with hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15(suppl):99.
30. Yeh R.F., Pawlikowski M.A., Blough D.K., et al. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011, [Epub ahead of print].